Our perspectives
in one place
Topic
Selected filters
ClearNews
See allIndustry commits to continued efforts to protect biodiversity at close of COP17
On the occasion of the 17th session of the Convention on Biological Diversity Conference of the Parties (COP17), Guilherme Cintra, Director, Innovation Policy, IFPMA said: “The pharmaceutical industry plays a central role in protecting health and recognizes that fulfilling this mission requires a healthy and biodiverse planet. “For this reason, we have long supported the...
Read more76th WHO Regional Committee for Europe: Roadmap for action on artificial intelligence in health in the WHO European Region 2026–2033
On 29 October 2026, IFPMA delivered a statement on the roadmap for action on artificial intelligence in health in the WHO European Region 2026–2033 at the 76th WHO Regional Committee for Europe in Copenhagen. We welcome efforts by WHO EURO to establish a pragmatic set of priorities toward meaningfully advancing AI in health. These efforts...
Read more76th WHO Regional Committee for Europe: Toward a strategy and action plan for tackling non-communicable diseases and advancing well-being through health promotion in the WHO European Region 2028-2037
On 29 October 2026, IFPMA submitted a statement on a strategy and action plan for tackling non-communicable diseases and advancing well being through health promotion in the WHO European Region 2028-2037 at the 76th WHO Regional Committee for Europe in Copenhagen. IFPMA and EFPIA welcome the document “Toward a strategy and action plan for tackling...
Read more76th WHO Regional Committee for Europe: Matters arising from Resolutions and Decisions of the World Health Assembly
On 28 October 2026, IFPMA submitted a statement on the global health architecture at the 76th WHO Regional Committee for Europe in Copenhagen. IFPMA welcomes the discussion on global health architecture reform and emphasizes the need for an architecture that fosters innovation, strengthens health systems, and forges partnerships that advance health globally. Reform should help...
Read more76th WHO Regional Committee for Europe Item 2: General debate
On 27 October 2026, IFPMA and EFPIA delivered a joint statement during the general debate of the 76th WHO Regional Committee for Europe in Copenhagen. The European region is currently facing a challenging environment of geopolitical tensions and open conflict, slow economic growth, declining competitiveness for life sciences, and increasing pressures on health systems. Against...
Read more17th meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD COP17)
IFPMA submitted a statement at the start of the 17th meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD COP17), which takes place 19-30 October in Yerevan, Armenia. Our statement is focused on item 11: digital sequence information (DSI) on genetic resources. IFPMA supports the conservation objectives of the Convention...
Read morePublications
See allHealthy planet, healthy people: The innovative pharmaceutical industry’s contribution to the Kunming-Montreal Global Biodiversity Framework
Through company-level initiatives and decades of pre-competitive collaboration, IFPMA member companies are working to reduce environmental impact and contribute positively to a healthy and biodiverse planet.
Read more
International data flows: Enabling data-driven, patient-centric innovative pharmaceutical research and development (R&D)
To fulfill the potential of data and new technologies in supporting the shared objective of improving patient lives and population health, it is vital that well-designed systems are put in place.
Read more
Enabling innovation: The R&D ecosystem for medicines and vaccines
Decisive policy action is critical to sustain innovation that improves people’s lives. This position paper illustrates the R&D ecosystem in action, and underscores the importance of continued commitment by governments and across stakeholders to ensure the conditions that enable the development and delivery of transformative medicines and vaccines.
Read more
Expert insights
See all
Business Strategy: Re-Centering Ethics as Pharma’s Competitive Advantage
Read more
Pharmaceutical innovation: A strategic investment in health and growth
Read more
From pilots to pipelines: What WIPO’s Global Innovation Index highlights about innovation ecosystems
Read moreResources
See allThe value of every 1% increase in influenza vaccination coverage
This IFPMA infographic shows how just a 1% increase in seasonal influenza vaccination coverage can deliver substantial health and economic benefits.
Read more
Adult immunization for healthy workforces and healthy economies in an aging world
IFPMA and the Global Coalition on Ageing (GCOA) outline why vaccination is essential to building healthier workforces and stronger economies in an aging world.
Read more
Streamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more